198206-29-0

Basic information

• Product Name: (2'-METHYLBIPHENYL-4-YL)-METHANOL
• Synonyms: (2'-METHYL[1,1'-BIPHENYL]-4-YL)METHANOL;(2'-METHYLBIPHENYL-4-YL)-METHANOL;AKOS BAR-1263;RARECHEM AL BD 1242;4-(2-Tolyl)benzyl alcohol;2'-Methyl-[1,1'-Biphenyl]-4-Methanol
• CAS NO: 198206-29-0
• Molecular Formula: C14H14O
• Molecular Weight: 198.26
• Mol File: 198206-29-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 334.8 °C at 760 mmHg
• Flash Point: 145.3 °C
• Appearance: /
• Density: 1.072 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (2'-METHYLBIPHENYL-4-YL)-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (2'-METHYLBIPHENYL-4-YL)-METHANOL(198206-29-0)
• EPA Substance Registry System: (2'-METHYLBIPHENYL-4-YL)-METHANOL(198206-29-0)

Safety Data

• Hazardous Substances Data: 198206-29-0(Hazardous Substances Data)

Usage

General Description

(2'-Methylbiphenyl-4-yl)-methanol is a chemical compound that belongs to the family of biphenyl-4-yl methanols. It is a white solid with a molecular formula of C14H14O. (2'-METHYLBIPHENYL-4-YL)-METHANOL is often used as a building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It has also been found to exhibit potential antioxidant and anti-inflammatory properties, making it a subject of interest in the field of medicinal chemistry. Additionally, it has been used as a starting material in the production of various types of plastics and polymers. Overall, (2'-methylbiphenyl-4-yl)-methanol has a wide range of potential applications in both the pharmaceutical and industrial sectors.

Upstream product

• 16419-60-6 2-Methylphenylboronic acid 
• 1122-91-4 4-bromo-benzaldehyde 
• 18282-51-4 4-iodo-benzyl alcohol 
• 6699-93-0 (2-methylphenyl)lithium 
• 105-13-5 4-Methoxybenzyl alcohol 
• 95-49-8 2-methylchlorobenzene 
• 59016-93-2 p-hydroxymethylphenylboronic acid 
• 586-76-5 4-Bromobenzoic acid 
• 5748-43-6 4-(2-methylphenyl)benzoic acid 
• 873-76-7 para-Chlorobenzyl alcohol 
• 893738-89-1 4′-(hydroxymethyl)biphenyl-2-carbaldehyde 
• 1332500-53-4 N'-((4'-(hydroxymethyl)biphenyl-2-yl)methylidene)-4-methylbenzenesulfonohydrazide 

Relevant articles and documents

Homo- and Heterobimetallic Complexes Bearing NHC Ligands: Applications in α-Arylation of Amide, Suzuki–Miyaura Coupling Reactions, and Tandem Catalysis

A heterobimetallic IrIII/PdII complex from a dicarbene donor ligand featuring cyclometalated IrIII and PEPPSI type PdII is presented along with a homodinuclear PEPPSI type PdII complex starting from the same bis-imidazolium salt. All the PdII complexes are active precatalyst in both α-arylation and Suzuki–Miyaura coupling reactions. The heterobimetallic IrIII/PdII complex shows much higher yields in tandem C–C coupling/transfer hydrogenation reactions compared to the equimolar mixture of their mononuclear PdII and IrIII counterparts.

Cross-Coupling of Organolithium with Ethers or Aryl Ammonium Salts by C?O or C?N Bond Cleavage

Various aryl-, alkenyl-, and/or alkyllithium species reacted smoothly with aryl and/or benzyl ethers with cleavage of the inert C?O bond to afford cross-coupled products, catalyzed by commercially available [Ni(cod)2] (cod=1,5-cyclooctadiene) catalysts with N-heterocyclic carbene (NHC) ligands. Furthermore, the coupling reaction between the aryllithium compounds and aryl ammonium salts proceeded under mild conditions with C?N bond cleavage in the presence of a [Pd(PPh3)2Cl2] catalyst. These methods enable selective sequential functionalizations of arenes having both C?N and C?O bonds in one pot.

CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS

Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.